Indian drug giant Aurobindo Pharma is reportedly leading the race to acquire Prague-based drugmaker Zentiva in a deal that could be worth up to $5.5 billion, according to a report by The Economic Times on Wednesday. If finalized, the acquisition would mark the largest-ever buyout by an Indian pharmaceutical company.
Aurobindo is in talks with U.S.-based private equity firm Advent International, which owns Zentiva, the report said, citing people aware of the matter.
However, Aurobindo issued a clarification in a statement to stock exchanges, saying that no binding agreements have been signed by the company’s board as of yet.
Read also: Aurobindo Pharma ramps up China facility production, eyes Q3 FY26 break even
In July, the company’s wholly owned subsidiary, Aurobindo Pharma USA Inc, entered into a definitive agreement to acquire 100% membership interest in Lannett Company LLC from Lannett Seller Holdco Inc.
Read also: Aurobindo Pharma Acquires Lannett for Rs 2,185 Cr to Boost U.S. Presence, ADHD Line
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 30 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and AntiAllergic, supported by a strong R&D set-up.
Read also: Aurobindo Pharma to manufacture, supply HIV treatment cabotegravir across 133 countries
